{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:14:13Z","timestamp":1767597253419},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s11899-018-0437-y","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T06:18:29Z","timestamp":1517552309000},"page":"37-43","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas\u2014Implications for Therapy"],"prefix":"10.1007","volume":"13","author":[{"given":"Eric","family":"Tse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yok-Lam","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"issue":"10","key":"437_CR1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nri3044","volume":"11","author":"JC Sun","year":"2011","unstructured":"Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat Rev Immunol. 2011;11(10):645\u201357. https:\/\/doi.org\/10.1038\/nri3044 .","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"437_CR2","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2217\/fon.11.84","volume":"7","author":"E Tse","year":"2011","unstructured":"Tse E, Kwong YL. Treatment algorithms for mature T-cell and natural killer-cell neoplasms. Future Oncol. 2011;7(9):1101\u201312. https:\/\/doi.org\/10.2217\/fon.11.84 .","journal-title":"Future Oncol"},{"key":"437_CR3","first-page":"190","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"ES Jaffe","year":"2017","unstructured":"Jaffe ES, Campo E, Harris NL, Pileri S, Stein H, Swerdlow SH. Introduction and overview of the classification of lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017. p. 190\u20138."},{"issue":"1","key":"437_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-017-0452-9","volume":"10","author":"E Tse","year":"2017","unstructured":"Tse E, Kwong YL. The diagnosis and management of NK\/T-cell lymphomas. J Hematol Oncol. 2017;10(1):85. https:\/\/doi.org\/10.1186\/s13045-017-0452-9 .","journal-title":"J Hematol Oncol"},{"issue":"9","key":"437_CR5","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S1470-2045(16)30148-6","volume":"17","author":"Z Li","year":"2016","unstructured":"Li Z, Xia Y, Feng LN, Chen JR, Li HM, Cui J, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 2016;17(9):1240\u20137. https:\/\/doi.org\/10.1016\/S1470-2045(16)30148-6 .","journal-title":"Lancet Oncol"},{"issue":"2","key":"437_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1349-7006.2010.01820.x","volume":"102","author":"S Sonoda","year":"2011","unstructured":"Sonoda S, Li HC, Tajima K. Ethnoepidemiology of HTLV-1 related diseases: ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal. Cancer Sci. 2011;102(2):295\u2013301. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01820.x .","journal-title":"Cancer Sci"},{"issue":"3","key":"437_CR7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1053\/j.gastro.2009.05.040","volume":"137","author":"J Romanos","year":"2009","unstructured":"Romanos J, van Diemen CC, Nolte IM, Trynka G, Zhernakova A, Fu J, et al. Analysis of HLA and non-HLA alleles can identify individuals at high risk for celiac disease. Gastroenterology. 2009;137(3):834\u201340. https:\/\/doi.org\/10.1053\/j.gastro.2009.05.040 .","journal-title":"Gastroenterology"},{"issue":"1","key":"437_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1056\/NEJMoa1313977","volume":"371","author":"E Liu","year":"2014","unstructured":"Liu E, Lee HS, Aronsson CA, Hagopian WA, Koletzko S, Rewers MJ, et al. Risk of pediatric celiac disease according to HLA haplotype and country. N Engl J Med. 2014;371(1):42\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1313977 .","journal-title":"N Engl J Med"},{"issue":"7","key":"437_CR9","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1001\/jama.2017.9730","volume":"318","author":"MM Leonard","year":"2017","unstructured":"Leonard MM, Sapone A, Catassi C, Fasano A. Celiac disease and nonceliac gluten sensitivity: a review. JAMA. 2017;318(7):647\u201356. https:\/\/doi.org\/10.1001\/jama.2017.9730 .","journal-title":"JAMA"},{"key":"437_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.semcancer.2015.06.001","volume":"34","author":"E Tse","year":"2015","unstructured":"\u2022 Tse E, Kwong YL. T-cell lymphoma: Microenvironment-related biomarkers. Semin Cancer Biol. 2015;34:46\u201351. A comprehensive review of potential biomarkers for response to treatment based on the microenvironment in T-cell lymphomas.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"437_CR11","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/bjc.2017.356","volume":"117","author":"S Aras","year":"2017","unstructured":"Aras S, Zaidi MR. TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer. 2017;117(11):1583\u201391. https:\/\/doi.org\/10.1038\/bjc.2017.356 .","journal-title":"Br J Cancer"},{"issue":"11","key":"437_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nri.2017.75","volume":"17","author":"L Lu","year":"2017","unstructured":"Lu L, Barbi J, Pan F. The regulation of immune tolerance by FOXP3. Nat Rev Immunol. 2017;17(11):703\u201371711. https:\/\/doi.org\/10.1038\/nri.2017.75 .","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"437_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2217\/imt-2017-0057","volume":"9","author":"T Enokida","year":"2017","unstructured":"Enokida T, Nishikawa H. Regulatory T cells, as a target in anticancer immunotherapy. Immunotherapy. 2017;9(8):623\u20137. https:\/\/doi.org\/10.2217\/imt-2017-0057 .","journal-title":"Immunotherapy"},{"key":"437_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semcancer.2013.11.004","volume":"24","author":"P Gaulard","year":"2014","unstructured":"\u2022 Gaulard P, de Leval L. The microenvironment in T-cell lymphomas: emerging themes. Semin Cancer Biol. 2014;24:49\u201360. a comprehensive review of the components of the microenvironment in T-cell lymphomas.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"437_CR15","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.immuni.2011.03.023","volume":"34","author":"YS Choi","year":"2011","unstructured":"Choi YS, Kageyama R, Eto D, Escobar TC, Johnston RJ, Monticelli L, et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity. 2011;34(6):932\u201346. https:\/\/doi.org\/10.1016\/j.immuni.2011.03.023 .","journal-title":"Immunity"},{"issue":"11","key":"437_CR16","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.celrep.2015.08.033","volume":"12","author":"F Kratochvill","year":"2015","unstructured":"Kratochvill F, Neale G, Haverkamp JM, Van de Velde LA, Smith AM, Kawauchi D, et al. TNF counterbalances the emergence of M2 tumor macrophages. Cell Rep. 2015;12(11):1902\u201314. https:\/\/doi.org\/10.1016\/j.celrep.2015.08.033 .","journal-title":"Cell Rep"},{"issue":"9","key":"437_CR17","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1182\/blood-2007-05-075176","volume":"110","author":"ST Pals","year":"2007","unstructured":"Pals ST, de Gorter DJ, Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. Blood. 2007;110(9):3102\u201311. https:\/\/doi.org\/10.1182\/blood-2007-05-075176 .","journal-title":"Blood"},{"issue":"4","key":"437_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/path.4920","volume":"242","author":"F Lemonnier","year":"2017","unstructured":"Lemonnier F, Mak TW. Angioimmunoblastic T-cell lymphoma: more than a disease of T follicular helper cells. J Pathol. 2017;242(4):387\u201390. https:\/\/doi.org\/10.1002\/path.4920 .","journal-title":"J Pathol"},{"issue":"2","key":"437_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/path.4898","volume":"242","author":"FH Schwartz","year":"2017","unstructured":"Schwartz FH, Cai Q, Fellmann E, Hartmann S, M\u00e4yr\u00e4np\u00e4\u00e4 MI, Karjalainen-Lindsberg ML, et al. TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. J Pathol. 2017;242(2):129\u201333. https:\/\/doi.org\/10.1002\/path.4898 .","journal-title":"J Pathol"},{"issue":"19","key":"437_CR20","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","volume":"123","author":"T Wang","year":"2014","unstructured":"\u2022\u2022 Wang T, Feldman AL, Wada DA, Lu Y, Polk A, Briski R, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014;123(19):3007\u201315. original observations of how gene expression profiles in T-cell lymphomas impact on microenvironmental changes and prognosis.","journal-title":"Blood"},{"issue":"7","key":"437_CR21","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood-2016-05-717793","volume":"129","author":"MT Werner","year":"2017","unstructured":"Werner MT, Zhao C, Zhang Q, Wasik MA. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. Blood. 2017;129(7):823\u201331. https:\/\/doi.org\/10.1182\/blood-2016-05-717793 .","journal-title":"Blood"},{"issue":"5","key":"437_CR22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","volume":"116","author":"JJ Campbell","year":"2010","unstructured":"Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767\u201371. https:\/\/doi.org\/10.1182\/blood-2009-11-251926 .","journal-title":"Blood"},{"issue":"1","key":"437_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/bjh.14402","volume":"176","author":"B Rubio-Gonzalez","year":"2017","unstructured":"Rubio-Gonzalez B, Zain J, Rosen ST, Querfeld C. Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions. Br J Haematol. 2017;176(1):16\u201336. https:\/\/doi.org\/10.1111\/bjh.14402 .","journal-title":"Br J Haematol"},{"issue":"13","key":"437_CR24","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","volume":"19","author":"BJ Chen","year":"2013","unstructured":"\u2022 Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462\u201373. original observations of how infection with Epstein Barr virus upregulates the expression of PDL1.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"437_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","volume":"9","author":"XW Bi","year":"2016","unstructured":"Bi XW, Wang H, Zhang WW, Wang JH, Liu WJ, Xia ZJ, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-\u03baB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma. J Hematol Oncol. 2016;9(1):109. https:\/\/doi.org\/10.1186\/s13045-016-0341-7 .","journal-title":"J Hematol Oncol"},{"issue":"7","key":"437_CR26","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00262-017-1987-x","volume":"66","author":"T Nagato","year":"2017","unstructured":"Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y, et al. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother. 2017;66(7):877\u201390. https:\/\/doi.org\/10.1007\/s00262-017-1987-x .","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"437_CR27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1440-1827.2010.02514.x","volume":"60","author":"D Niino","year":"2010","unstructured":"Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, Hashikawa K, et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for angioimmunoblastic T-cell lymphoma (AITL). Pathol Int. 2010;60(4):278\u201383. https:\/\/doi.org\/10.1111\/j.1440-1827.2010.02514.x .","journal-title":"Pathol Int"},{"issue":"3","key":"437_CR28","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/cancers6031670","volume":"6","author":"T Chanmee","year":"2014","unstructured":"Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel). 2014;6(3):1670\u201390. https:\/\/doi.org\/10.3390\/cancers6031670 .","journal-title":"Cancers (Basel)"},{"issue":"19","key":"437_CR29","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","volume":"123","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915\u201323.","journal-title":"Blood"},{"issue":"1","key":"437_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","volume":"13","author":"CL Batlevi","year":"2016","unstructured":"Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2016;13(1):25\u201340. https:\/\/doi.org\/10.1038\/nrclinonc.2015.187 .","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"437_CR31","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/jid.2014.206","volume":"134","author":"X Wu","year":"2014","unstructured":"Wu X, Schulte BC, Zhou Y, Haribhai D, Mackinnon AC, Plaza JA, et al. Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. J Invest Dermatol. 2014;134(11):2814\u201322. https:\/\/doi.org\/10.1038\/jid.2014.206 .","journal-title":"J Invest Dermatol"},{"issue":"9","key":"437_CR32","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/ng.3356","volume":"47","author":"J Choi","year":"2015","unstructured":"Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47(9):1011\u20139. https:\/\/doi.org\/10.1038\/ng.3356 .","journal-title":"Nat Genet"},{"issue":"15","key":"437_CR33","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1073\/pnas.1700682114","volume":"114","author":"J Chen","year":"2017","unstructured":"Chen J, Zhang Y, Petrus MN, Xiao W, Nicolae A, Raffeld M, et al. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1\/STAT3 mutations. Proc Natl Acad Sci U S A. 2017;114(15):3975\u201380. https:\/\/doi.org\/10.1073\/pnas.1700682114 .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"437_CR34","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3324\/haematol.2011.061507","volume":"97","author":"MH Delfau-Larue","year":"2012","unstructured":"Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Challine D, Parrens M, et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica. 2012;97(10):1594\u2013602. https:\/\/doi.org\/10.3324\/haematol.2011.061507 .","journal-title":"Haematologica"},{"issue":"14","key":"437_CR35","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1182\/blood-2014-05-578286","volume":"124","author":"AP Kater","year":"2014","unstructured":"Kater AP, Tonino SH, Egle A, Ramsay AG. How does lenalidomide target the chronic lymphocytic leukemia microenvironment? Blood. 2014;124(14):2184\u20139. https:\/\/doi.org\/10.1182\/blood-2014-05-578286 .","journal-title":"Blood"},{"issue":"5","key":"437_CR36","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/cncr.29103","volume":"121","author":"E Toumishey","year":"2015","unstructured":"Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer. 2015;121(5):716\u201323. https:\/\/doi.org\/10.1002\/cncr.29103 .","journal-title":"Cancer"},{"issue":"8","key":"437_CR37","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood-2013-09-525915","volume":"123","author":"C Querfeld","year":"2014","unstructured":"Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, et al. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and S\u00e9zary syndrome. Blood. 2014;123(8):1159\u201366. https:\/\/doi.org\/10.1182\/blood-2013-09-525915 .","journal-title":"Blood"},{"issue":"11","key":"437_CR38","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1038\/sj.leu.2403936","volume":"19","author":"I Bruns","year":"2005","unstructured":"Bruns I, Fox F, Reinecke P, Kobbe G, Kronenwett R, Jung G, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia. 2005;19(11):1993\u20135. https:\/\/doi.org\/10.1038\/sj.leu.2403936 .","journal-title":"Leukemia"},{"issue":"2","key":"437_CR39","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/annonc\/mdm579","volume":"19","author":"D Aguiar Bujanda","year":"2008","unstructured":"Aguiar Bujanda D. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann Oncol. 2008;19(2):396\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdm579 .","journal-title":"Ann Oncol"},{"issue":"4","key":"437_CR40","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3109\/10428194.2013.816700","volume":"55","author":"K Ganjoo","year":"2014","unstructured":"Ganjoo K, Hong F, Horning SJ, Gascoyne RD, Natkunam Y, Swinnen LJ, et al. Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma. 2014;55(4):768\u201372. https:\/\/doi.org\/10.3109\/10428194.2013.816700 .","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"437_CR41","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157\u201363. https:\/\/doi.org\/10.1200\/JCO.2013.52.0924 .","journal-title":"J Clin Oncol"},{"issue":"12","key":"437_CR42","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","volume":"125","author":"M Duvic","year":"2015","unstructured":"Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, et al. Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883\u20139. https:\/\/doi.org\/10.1182\/blood-2014-09-600924 .","journal-title":"Blood"},{"issue":"44","key":"437_CR43","doi-asserted-by":"publisher","first-page":"17945","DOI":"10.1073\/pnas.1316796110","volume":"110","author":"D Sugiyama","year":"2013","unstructured":"Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A. 2013;110(44):17945\u201350. https:\/\/doi.org\/10.1073\/pnas.1316796110 .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"437_CR44","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698\u2013704. https:\/\/doi.org\/10.1200\/JCO.2015.65.9789 .","journal-title":"J Clin Oncol"},{"key":"437_CR45","doi-asserted-by":"crossref","unstructured":"Chan TSY, Li J, Loong F, Khong PL, Tse E, Kwong YL. PD1 blockade with low-dose nivolumab in NK\/T cell lymphoma failing L-asparaginase: efficacy and safety. Ann Hematol. 2017.","DOI":"10.1007\/s00277-017-3127-2"},{"issue":"7683","key":"437_CR46","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nature24649","volume":"552","author":"T Wartewig","year":"2017","unstructured":"Wartewig T, Kurgyis Z, Keppler S, Pechloff K, Hameister E, \u00d6llinger R, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017;552(7683):121\u20135. https:\/\/doi.org\/10.1038\/nature24649 .","journal-title":"Nature"},{"issue":"17","key":"437_CR47","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"YL Kwong","year":"2017","unstructured":"\u2022 Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood. 2017;129(17):2437\u201342. original observations of the high efficacy of PD1 blockade in NK-cell lymphoma.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-018-0437-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-018-0437-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-018-0437-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T05:07:01Z","timestamp":1570684021000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-018-0437-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1007\/s11899-018-0437-y","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"2 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}